SFM
CEROW

Spartan Fund Management’s CERo Therapeutics Warrants CEROW Stock Holding History

Spartan Fund Management’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-25,000
Closed -$688 – 138
2023
Q4 		$688 Hold
25,000
– – ﹤0.01% 197
2023
Q3 		$1.79K Sell
25,000
-78,423
-76% -$5.61K ﹤0.01% 243
2023
Q2 		$3.27K Buy
103,423
+78,423
+314% +$3.4K ﹤0.01% 305
2023
Q1 		$1K Hold
25,000
– – ﹤0.01% 337
2022
Q4 		$1K Hold
25,000
– – ﹤0.01% 373
2022
Q3 		$2K Buy
+25,000
New +$2.1K ﹤0.01% 402

Other funds holding CEROW

HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.57% 1-Year Est. Return

Spartan Fund Management's CEROW Position: Q1 2024 in Review

Spartan Fund Management sold out of CERo Therapeutics Warrants (CEROW) in Q1 2024, closing a stake of 25,000 shares — an estimated $688 sold.

Spartan Fund Management first reported a position in CEROW in Q3 2022 and held it in 6 quarters. The position peaked at $3.27K in Q2 2023. 37 funds tracked by Wall St. Rank hold CEROW as of Q1 2024.

  • Spartan Fund Management reported no remaining CERo Therapeutics Warrants position as of Q1 2024 after selling out during the quarter.
  • Spartan Fund Management sold 25,000 CERo Therapeutics Warrants shares in Q1 2024, an estimated $688.
  • Spartan Fund Management first reported a position in CERo Therapeutics Warrants in Q3 2022 and held it in 6 quarters.
  • Spartan Fund Management's CERo Therapeutics Warrants position peaked at $3.27K in Q2 2023.
  • 37 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q1 2024.

Based on Spartan Fund Management's 13F filing for Q1 2024, filed 23 Apr 2024.